United Therapeutics Corp
UTHR440.000USD
-5.380-1.21%
Cierre 10/10, 16:00（ET）Cotizaciones retrasadas 15 min
19.89BCap. mercado
16.02P/E TTM
Más Datos de United Therapeutics Corp Compañía
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Información de United Therapeutics Corp
Símbolo de cotizaciónUTHR
Nombre de la empresaUnited Therapeutics Corp
Fecha de salida a bolsaJun 17, 1999
Director ejecutivoDr. Martine A. Rothblatt
Número de empleados1305
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 17
Dirección1000 Spring St
CiudadSILVER SPRING
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20910
Teléfono13016089292
Sitio Webhttps://www.unither.com/
Símbolo de cotizaciónUTHR
Fecha de salida a bolsaJun 17, 1999
Director ejecutivoDr. Martine A. Rothblatt
Ejecutivos de United Therapeutics Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
+29.50%
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
520.00
-57.38%
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Tyvaso DPI
315.20M
39.47%
Nebulized Tyvaso
168.30M
21.07%
Remodulin
155.70M
19.50%
Orenitram
123.90M
15.51%
Unituxin
61.40M
7.69%
Otro
-25.90M
-3.24%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
798.60M
100.00%
Rest of World
38.80M
4.86%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Tyvaso DPI
315.20M
39.47%
Nebulized Tyvaso
168.30M
21.07%
Remodulin
155.70M
19.50%
Orenitram
123.90M
15.51%
Unituxin
61.40M
7.69%
Otro
-25.90M
-3.24%
Estadísticas de accionistas
Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.79%
BlackRock Institutional Trust Company, N.A.
9.59%
Avoro Capital Advisors LLC
5.24%
State Street Global Advisors (US)
4.79%
Renaissance Technologies LLC
4.69%
Otro
65.89%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.79%
BlackRock Institutional Trust Company, N.A.
9.59%
Avoro Capital Advisors LLC
5.24%
State Street Global Advisors (US)
4.79%
Renaissance Technologies LLC
4.69%
Otro
65.89%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
42.73%
Investment Advisor/Hedge Fund
37.74%
Hedge Fund
9.19%
Pension Fund
4.79%
Individual Investor
1.75%
Research Firm
1.73%
Bank and Trust
1.44%
Sovereign Wealth Fund
1.25%
Venture Capital
0.46%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1330
44.91M
99.30%
-3.12M
2025Q2
1338
46.42M
102.62%
-2.51M
2025Q1
1369
46.67M
103.49%
-1.81M
2024Q4
1344
46.07M
102.60%
-3.00M
2024Q3
1278
45.38M
101.97%
-7.63M
2024Q2
1219
48.02M
108.26%
-2.92M
2024Q1
1151
47.12M
106.59%
-2.41M
2023Q4
1127
46.52M
99.01%
-2.26M
2023Q3
1094
46.35M
98.80%
-3.96M
2023Q2
1068
46.82M
99.96%
-3.45M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
4.43M
9.79%
-8.97K
-0.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.34M
9.59%
-138.61K
-3.10%
Jun 30, 2025
Avoro Capital Advisors LLC
2.37M
5.24%
-305.00K
-11.40%
Jun 30, 2025
State Street Global Advisors (US)
2.17M
4.79%
-63.20K
-2.83%
Jun 30, 2025
Renaissance Technologies LLC
2.12M
4.69%
+12.10K
+0.57%
Jun 30, 2025
Wellington Management Company, LLP
1.44M
3.19%
-583.48K
-28.79%
Jun 30, 2025
AQR Capital Management, LLC
1.27M
2.82%
+364.71K
+40.15%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.20M
2.65%
-23.63K
-1.93%
Jun 30, 2025
LSV Asset Management
864.62K
1.91%
-37.70K
-4.18%
Jun 30, 2025
Invesco Capital Management LLC
821.69K
1.82%
+445.52K
+118.44%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: lun., 6 de oct
Actualizado: lun., 6 de oct
Nombre
Proporción
Invesco Biotechnology & Genome ETF
4.57%
First Trust NASDAQ Pharmaceuticals ETF
3.59%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Formidable Fortress ETF
2.96%
Franklin Genomic Advancements ETF
2.73%
SPDR S&P Biotech ETF
2.57%
Inspire Faithward Mid Cap Momentum ETF
2.52%
Invesco S&P MidCap Quality ETF
2.42%
Invesco Pharmaceuticals ETF
2.3%
First Trust Health Care Alphadex Fund
2.28%
Ver más
Invesco Biotechnology & Genome ETF
Proporción4.57%
First Trust NASDAQ Pharmaceuticals ETF
Proporción3.59%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.34%
Formidable Fortress ETF
Proporción2.96%
Franklin Genomic Advancements ETF
Proporción2.73%
SPDR S&P Biotech ETF
Proporción2.57%
Inspire Faithward Mid Cap Momentum ETF
Proporción2.52%
Invesco S&P MidCap Quality ETF
Proporción2.42%
Invesco Pharmaceuticals ETF
Proporción2.3%
First Trust Health Care Alphadex Fund
Proporción2.28%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
